Eyevensys
Platforms for long acting non-viral gene therapy for ocular diseases.
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
PulseSight is a biotechnology company focused on developing innovative treatments for Age-related Macular Degeneration (AMD), a leading cause of irreversible vision loss in the elderly. The company operates in the pharmaceutical and biotech market, primarily serving patients and healthcare providers dealing with complex retinal diseases. PulseSight's core product, PST 809, is a first-in-class treatment that uniquely targets both VEGF and VEGF-independent pathways, differentiating it from existing anti-VEGF therapies. This dual-targeting approach aims to inhibit pathogenic cascades involved in angiogenesis, inflammation, and subretinal fibrosis, thereby offering a more comprehensive solution for AMD. The company generates revenue through the development and commercialization of its proprietary treatments, aiming to address the unmet needs in the AMD market, which is projected to reach $27.5 billion by 2031. PulseSight's business model includes partnerships with pharmaceutical companies and healthcare providers to bring its innovative therapies to market.
Keywords: AMD, biotechnology, VEGF, vision loss, retinal diseases, PST 809, angiogenesis, inflammation, subretinal fibrosis, pharmaceutical.